glp·helper
glphelper.com/semaglutide/florida/palm-coast
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Palm Coast, FL

Verified Semaglutide providers in Palm Coast, FL. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
29
as of today
§ 02Provider directory: Florida
29 of 29 shown

Find a Semaglutide provider in Florida.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by Florida city · /semaglutide/florida/{city}
§ 03Getting Semaglutide in Palm Coast
29 providers · Palm Coast, FL

How to get Semaglutide in Palm Coast.

29 GLP-1 prescribers and 7 local resource types are on record for Palm Coast, plus 3 nearby towns in the directory.

Prescribers in Palm Coast
29 prescribers
29 GLP-1 prescribers in Palm Coast, most listed as Family Medicine (12), Internal Medicine (9) and Internal Medicine, Endocrinology, Diabetes & Metabolism (3). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Daytona Beach (32 providers), DeLand (23 providers) and New Smyrna Beach (25 providers).
Around the prescription in Palm Coast
7 listed nearby
11 dietitians, 2 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Palm Coast.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Palm Coast

Palm Coast, Florida has a population of 89,258 people. The adult obesity rate in Palm Coast is an age-adjusted estimate of 31.2%, 1.6 percentage points above the Florida state rate of 29.6%. Diagnosed diabetes reaches 9.5% of adults in Palm Coast. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 22.2% of adults in Palm Coast.

of Palm Coast adults have obesity
31.2%
diagnosed diabetes
9.5%
no regular physical activity
22.2%

Age-adjusted estimates for Palm Coast, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossGLP-1s and fertility
§ 05Support around Semaglutide in Palm Coast
6 fitness clubs

The prescription is one part. Here is the rest, in Palm Coast.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Palm Coast, FL, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Mission Ready CrossFit
FITNESS
4.9 on Google · 43 reviews
24 Old Kings Rd N
Website
Hour of Power Fitness
FITNESS
5.0 on Google · 15 reviews
4721 E Moody Blvd #106
Planet Fitness
GYM
4.0 on Google · 734 reviews
7 Old Kings Rd N Units 20-32
Website
Southside Strength Gym and Personal Training
GYM
5.0 on Google · 145 reviews
501 N State St
Website
Just Train Fitness
GYM
4.7 on Google · 79 reviews
300 Palm Coast Pkwy SW #5
Website
Balance Palm Coast LLC
STUDIO
4.9 on Google · 34 reviews
101 Palm Harbor Pkwy Unit 106
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Michelle Bermeo
RD
Registered dietitian
60 Memorial Medical Pkwy
Call 386-586-1848NPI 1518711621
Victoria Bongiorno, MS, RD, CPT
RD
Registered dietitian
463 Grand Landings Pkwy
Call 406-880-5243NPI 1912743774
Jilann Doucette, RD, LDN
RD
Registered dietitian
1 Farraday Ln Unit F
Call 386-523-6672NPI 1740836329
Shelly Edens, R.D., C.S.O., L.D.N
RD
Registered dietitian
60 Memorial Medical Pkwy
Call 386-586-4320NPI 1093139677
Rhonda Filetti, RD, CDCES
RD
Registered dietitian
305 Memorial Medical Pkwy Ste 101
Call 386-231-3177NPI 1811689284
Lindsay Garcia, MCN, RD
RD
Registered dietitian
12902 Usf Magnolia Dr
Call 888-663-3488NPI 1134735442
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Florida

NPI-verified Semaglutide (semaglutide) prescribers and clinics, never ranked by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]